Merida Biosciences
Focus: Merida Biosciences is a 2024-founded Cambridge biotech focused on therapies that eliminate pathogenic antibodies, targeting autoimmune and other antibody-driven diseases. The company is pre-revenue and in early-stage development.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About Merida Biosciences
AI assessmentNot HiringNo open roles listed right now. Follow Merida Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Visionary: computer exercises using dichoptic Gabor Patches and band-filtered noise masks
AmblyopiaClinical Trials (1)
NCT06150391Evaluation of Amblyopia Protocols Using a Dichoptic Gabor Videogame Program
N/AHelp build intelligence for Merida Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.